JPS62255431A - Composition for normalizing liver function - Google Patents
Composition for normalizing liver functionInfo
- Publication number
- JPS62255431A JPS62255431A JP61098181A JP9818186A JPS62255431A JP S62255431 A JPS62255431 A JP S62255431A JP 61098181 A JP61098181 A JP 61098181A JP 9818186 A JP9818186 A JP 9818186A JP S62255431 A JPS62255431 A JP S62255431A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- ginkgo
- liver function
- leaves
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 11
- 239000000284 extract Substances 0.000 abstract description 24
- 241000218628 Ginkgo Species 0.000 abstract description 15
- 235000011201 Ginkgo Nutrition 0.000 abstract description 15
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003960 organic solvent Substances 0.000 abstract description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 9
- 238000000605 extraction Methods 0.000 abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003935 flavonoid Natural products 0.000 abstract description 4
- 150000002215 flavonoids Chemical class 0.000 abstract description 4
- 235000017173 flavonoids Nutrition 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 241000510032 Ellipsaria lineolata Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 aliphatic alcohols Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000533770 Cayaponia Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
発明の技術分野
本発明は、肝機能の正常化に有効ないちょう葉エキスを
含む組成物に関する。DETAILED DESCRIPTION OF THE INVENTION Technical Field of the Invention The present invention relates to a composition containing a butterfly leaf extract effective in normalizing liver function.
発明の技術的背理ならびにその問題点
いらようは広く日本国内に存在しているが、このいちょ
うの緑の状態に必る葉（以下いうよう菓と略記すること
がある）には、種々の有効成分が含有されていることが
知られている。たとえば特公昭４６−２８０９１号公報
には、いちょう葉中に脂肪族アルコール類、ケ１〜ン類
、ギンクゴライド類、フラボノイド類か含まれており、
フラボノイド類としてはガロカテキン、カロエヒ゛カデ
キン、プロデルフエニシン、フラボングツシト、ピフラ
ホンなどが含有されていると報告されている。そして同
公報には、いらよう葉からこれらの有効成分を抽出して
１ｑられるいちょう葉エキス組成物が持に老人における
末梢および大脳動脈の血流障害の治療に効果がおると記
載されている。Although the technical inconsistency of the invention and its problems are widespread in Japan, there are various effective It is known that it contains ingredients. For example, Japanese Patent Publication No. 46-28091 discloses that ginkgo leaves contain aliphatic alcohols, carbons, ginkgolides, and flavonoids.
It has been reported that flavonoids include gallocatechin, caroehyacadechin, proderphenicin, flavone, piflaphone, etc. The same publication states that a ginkgo leaf extract composition prepared by extracting these active ingredients from the japonica leaf is particularly effective in treating peripheral and cerebral arterial blood flow disorders in the elderly.
また持間昭６０−１０９５２２号公報には、上記のよう
ないちょう葉エキス組成物が神経障害、特に脳疾患など
に対して侵れた効果を右することが記載されている。Furthermore, Mochima Publication No. 109522/1987 describes that the above-mentioned butterfly extract composition has effects on neurological disorders, particularly brain diseases.
ところで今や肝臓病は結核にかわって第２の国民病とな
ったといわれるように、日本国内においては多くの人々
が急性肝炎などの肝臓病によって悩まされている。また
肝臓病はアルコールの摂取♀と密接な関係があるとされ
ており、酒飲みの人々にとっては、肝機能か正常でおる
か否かは常に気になることで必る。このように肝臓に対
する国民の関心は伺めて高く、もし肝機能の正常化にイ
１効であって、しかし服用あるいは摂取によって何らの
ＪＪ作用も牛しないよう／よらのが見出されれば、極め
て価値あることで必ろうと考えられる。By the way, it is said that liver disease has now replaced tuberculosis as the second national disease, and many people in Japan are suffering from liver diseases such as acute hepatitis. Furthermore, liver disease is said to be closely related to alcohol intake, and people who drink alcohol are always concerned about whether their liver function is normal or not. As described above, the public's interest in the liver is clearly high, and if it is found that it is effective in normalizing liver function, but does not cause any JJ effects when taken or ingested, it would be extremely effective. It is considered necessary because it is valuable.
発明の目的
本発明は、肝機能の正常化に有効であるとともに、長期
間にわたって飲み続けても何らの副作用あるいは害のな
いような天然系の肝機能正常化用組成物を提供すること
を目的としている。Purpose of the Invention The purpose of the present invention is to provide a natural composition for normalizing liver function that is effective for normalizing liver function and does not cause any side effects or harm even if taken continuously for a long period of time. It is said that
発明の概要
本発明に係る肝機能正常化用組成物は、いちょう菓エキ
スを有効成分として含むことを特徴としている。Summary of the Invention The composition for normalizing liver function according to the present invention is characterized by containing Ginkgo confectionery extract as an active ingredient.
本発明に係る肝機能正常化用組成物は、緑の状態にある
いちょう葉から得られるいちょう葉エキスを有効成分と
して含んでおり、この組成物を飲み続けるとＧＰＴ、Ｇ
ＯＴによって示される肝機能が徐々に正常化される。し
かも本発明に係る肝）幾重正常１ヒ用組成物は、天然の
植物葉から抽出したものでおるので長期間にわたって飲
み続けても何らの副作用も認められない。The composition for normalizing liver function according to the present invention contains ginkgo leaf extract obtained from green ginkgo leaves as an active ingredient.
Liver function as indicated by OT is gradually normalized. Moreover, since the composition for normal liver and liver disease according to the present invention is extracted from natural plant leaves, no side effects are observed even if the composition is taken continuously for a long period of time.
発明の詳細な説明
以下本発明に係る肝機能正常化用組成物について具体的
に説明する。DETAILED DESCRIPTION OF THE INVENTION The composition for normalizing liver function according to the present invention will be specifically described below.
本発明に係る肝機能正常化用組成物は、いちょう葉エキ
スを有効成分として含んでおり、まずこのいちょう葉エ
キスの製造方法について説明する。The composition for normalizing liver function according to the present invention contains ginkgo leaf extract as an active ingredient, and first, a method for producing this ginkgo leaf extract will be explained.
いらよう菓エキスを製造するに際して用いられるいらよ
う葉は、緑の状態にあるものが用いられ、黄変した状態
にあるものは用いられない。なぜなら黄変したいちょう
菓には、有効成分が必まり含まれていないからで必る。The leaves that are used in the production of Irayouka extract are those that are in a green state, and those that are in a yellowed state are not used. This is because yellowing ginkgo confectionery does not necessarily contain active ingredients.
またいちょう葉は、予じめ乾燥されて砕かれた状態とし
て、以下に述べる抽出工程に付されることが好ましい。Moreover, it is preferable that the ginkgo leaves be dried and crushed in advance and subjected to the extraction process described below.
このようないちょう葉を、約４０〜１００℃、好ましく
は６０〜８０℃の温度において、水と混和しうる有機溶
媒と水との混合物で抽出処理する。Such butterfly leaves are extracted with a mixture of water and an organic solvent miscible with water at a temperature of about 40 to 100°C, preferably 60 to 80°C.
この際抽出時間は、１〜１０時間好ましくは３〜７時間
程度であり、抽出圧力としては常圧おるいは加圧条件が
採用される。抽出操作の終了後、圧搾処理などにより、
抽出液をいちょう菓から分離する。At this time, the extraction time is about 1 to 10 hours, preferably about 3 to 7 hours, and the extraction pressure is normal pressure or pressurized conditions. After the extraction operation is completed, through the pressing process, etc.
Separate the extract from the ginkgo sweets.
水と混和しうる有機溶媒としては、具体的には、アセト
ン、メヂルエチルケトン、ジエチルケトンなどのケトン
類コあるいはメタノール、エタノール、ｎ−プロパツー
ル、イソプロパツール、ブタノールなどの低級アルコー
ル類などが用いられる。Examples of organic solvents that are miscible with water include ketones such as acetone, methyl ethyl ketone, and diethyl ketone, and lower alcohols such as methanol, ethanol, n-propanol, isopropanol, and butanol. is used.
このような水と混和しうる有機溶媒は、水と混合されて
用いられるが、この有機溶媒は混合物中で５０〜８０Ｗ
ｆｆ１％の四で用いられる。Such water-miscible organic solvents are used by being mixed with water;
It is used in 4 of ff1%.
次に、このようにして得られた含水有機溶媒油出液に、
水と実質的に混和しない有機溶媒を加えて、約１５〜５
０℃の温度において抽出操作を行なう。この際用いられ
る水と実質的に混和しない有機溶媒としては、クロロホ
ルム、四基化炭Ｒ、メチレンジクロライドなどの脂溶性
溶媒が用いられる。Next, to the water-containing organic solvent oil extract obtained in this way,
Adding an organic solvent that is substantially immiscible with water, approximately 15 to 5
The extraction operation is carried out at a temperature of 0°C. As the organic solvent used in this case that is substantially immiscible with water, fat-soluble solvents such as chloroform, tetracarbon R, and methylene dichloride are used.
上記のような抽出操作が加えられた含水有機溶媒抽出液
から、有機溶媒を減圧蒸留などによって除去すると、本
発明に係るいちょう葉エキスが得られる。もし必要で必
れば、このいらよう葉エキスを減圧下で乾燥させること
によって粉末状のいらよう葉エキスとすることもできる
。The ginkgo leaf extract according to the present invention can be obtained by removing the organic solvent from the water-containing organic solvent extract subjected to the above-described extraction operation by vacuum distillation or the like. If necessary, this extract can be made into a powdered extract by drying it under reduced pressure.
またもし必要であれば、緑の状態にあるいちょう葉を約
４０〜１００’Ｃの温度にて水と混和しうる含水有機溶
媒で抽出し、得られた抽出液を約１５〜５０℃において
水と混和しない脂溶性有償溶媒で抽出した後、含水有機
溶媒抽出液に硫酸アンモニウムを加え、沸点約６０〜１
００℃であって水に対しである程度の溶解性を有する有
機溶媒で抽出し、この抽出液を濃縮後、残留物を低級ア
ルコールで抽出し、抽出液から溶媒を除去することにに
つて、いらよう葉エキスを調製してもよい。If necessary, the ginkgo leaves in the green state are extracted with a water-containing organic solvent that is miscible with water at a temperature of about 40 to 100'C, and the resulting extract is poured into water at a temperature of about 15 to 50'C. After extraction with a fat-soluble paid solvent that is immiscible with
Extracting with an organic solvent that has a certain degree of solubility in water at 00°C, concentrating this extract, extracting the residue with lower alcohol, and removing the solvent from the extract. A melon leaf extract may also be prepared.
このようにすると、ざらに精製されたいちょう葉エキス
とすることができる。In this way, a roughly purified ginkgo leaf extract can be obtained.
このようにして得られるいちょう葉エキス中には、いち
ょう菓に含まれるフラボノイド類を始めとして種々の有
効成分が含まれているが、脂溶性物質は除去されている
。The ginkgo leaf extract obtained in this way contains various active ingredients including flavonoids contained in ginkgo sweets, but fat-soluble substances have been removed.
このようにして得られたいちょう葉エキスは、たとえば
カプセル化されたり、錠剤化または顆粒化されたり、お
るいはそのままの状態で、使用に供される。The ginkgo leaf extract thus obtained can be used, for example, in the form of capsules, tablets, or granules, or as it is.
また必要に応じては、いらよう菓エキス中に、ビタミン
Ｅ、ビタミンＣ，などのビタミン類、必るいはベニバナ
油などの食用油を添加して用いることもできる１゜
本発明に係る１拝機能正常化用組成物は、緑の状態にあ
るいちょう葉から１ｑられるいちょう葉エキスを有効成
分として含んでおり、この組成物を飲み続けるとＧＰＴ
、ＧＯＨによって示される肝機能か徐々に正常化される
。If necessary, vitamins such as vitamin E, vitamin C, or edible oil such as safflower oil may be added to the irayouka extract. The composition for normalizing functions contains as an active ingredient ginkgo leaf extract obtained from 1q ginkgo leaves in the green state, and if you continue to drink this composition, GPT
, liver function as indicated by GOH is gradually normalized.
以下本発明で用いられるいらよう葉エキスの：摸造方法
について具体的に説明する。 。Hereinafter, the method for imitating the porphyry leaf extract used in the present invention will be specifically explained. .
乾燥し粗く砕いたいらよう緑葉１００Ｋｙを抽出殿に入
れ、６０％アレ１ヘン水溶液５００Ｆを用いて約５５°
Ｃで約５時間抽出処理し、その混合物を冷却した後、抽
出液をいちょう葉から分離した。Put 100Ky of dried and coarsely crushed Irayo green leaves into the extraction chamber and heat at about 55° using 500F of 60% Aleben aqueous solution.
After extracting with C for about 5 hours and cooling the mixture, the extract was separated from the ginkgo leaves.
得られた水性抽出液を、四塩化炭素６０．０を用いて攪
拌しながら２回抽出し、四塩化炭素層を分離した。水性
アセトン層を減圧下で蒸留してアセトンを留去し、吸湿
性残渣を減圧下約５０℃で乾燥して、粉末状とした。The resulting aqueous extract was extracted twice with 60.0 g of carbon tetrachloride while stirring, and the carbon tetrachloride layer was separated. The aqueous acetone layer was distilled under reduced pressure to remove the acetone, and the hygroscopic residue was dried under reduced pressure at about 50° C. to form a powder.
この粉末状物中には、フラボイトか含有されていること
か、フラボイド試某であるジフェニル囲酸β−アミノエ
チルエステルによる発色反応で確かめられた。The presence of flavoites in this powder was confirmed by a coloring reaction with diphenylperisic acid β-aminoethyl ester, which is a flavoid test.
次に上記のようにしてｊｑられた粉末状いらよう菓エギ
スを有効成分して含む水性組成物を臨床試験に用いた結
果について説明する。なＪ′３この臨床試験は、北海道
に必る原子弘漢療法院ｄ５よσ北盛医院において行なわ
れた。Next, the results of using an aqueous composition containing as an active ingredient the powdered Egisu powder prepared as described above in a clinical trial will be explained. This clinical trial was conducted at Atomic Kokan Therapy Clinic D5 and σ Kitamori Hospital in Hokkaido.
試験例１
ＧＯＴＩ直が５１であり、ＧＰＴ（直が３４であり肝機
能にやや異常の認められる６２才の女性に、いちょう葉
エキスを毎日１５０ｍｇづつｔＵえ続けて２０日後に再
度ＧＯＴおよびＧＰＴを検査したところ、ＧＯＨ値は１
７どなりＧＰＴ値は１１と正常値の範囲になった。Test Example 1 A 62-year-old woman with a GOTI score of 51 and a GPT score of 34 with slight abnormalities in liver function was given Ginkgo biloba extract at a dose of 150 mg every day, and 20 days later, she was given GOT and GPT again. Upon inspection, the GOH value was 1.
The GPT value was 11, which is within the normal range.
なお正常な人の場合のＧＯＨ値は４０以下であり、ＧＰ
Ｔ値は３５以下である。In addition, the GOH value for a normal person is 40 or less, and the GP
The T value is 35 or less.
試験例２
ＧＯＴ（直が５４でおり、ＧＰＴ（直が３６で必り肝機
能にやや異常の９こめられる５６オの男性に、いもよう
葉エキスを毎日１５０／７１１９づつ与え続けて１８日
後に再度ＧＯＴおよびＧＰＴを検査したところ、ＧＯＴ
（直は１２となりＧＰＴ値は８と正常値の範囲になった
。Test Example 2 A 56-year-old man with a GOT of 54 and a GPT of 36 and a slightly abnormal liver function was given 150/7119 portions of potato leaf extract every day for 18 days. After inspecting GOT and GPT again, GOT
(His score was 12 and his GPT value was 8, which is within the normal range.
試験例３
ＧＯＴｆ直が６９であり、ＧＰＴｆ直が５４でおり肝機
能にやや異常の認められる４８才の男性に、いちょう菓
エキスを毎日１５０ｍｇづつ与え続けて２１日後に再度
Ｇ ＯＴおＪ：びＧＰＴを検査したところ、ＧＯＨ値は
３９となりＧＰＴ値は３１と正常値の範囲になった。Test Example 3 A 48-year-old man with a GOTf direct of 69 and a GPTf direct of 54 with slight abnormalities in liver function was given 150 mg of Ichoka extract daily, and 21 days later, he was given GOT OJ:bis again. When GPT was tested, the GOH value was 39 and the GPT value was 31, which was within the normal range.
Claims (1)
とする肝機能正常化用組成物1) A composition for normalizing liver function characterized by containing ginkgo leaf extract as an active ingredient
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61098181A JPS62255431A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing liver function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61098181A JPS62255431A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing liver function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62255431A true JPS62255431A (en) | 1987-11-07 |
Family
ID=14212851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61098181A Pending JPS62255431A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing liver function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62255431A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004002335A (en) * | 2002-03-28 | 2004-01-08 | Ortho Corporation | Agent for ameliorating symptom of indefinite complaint, food and composition thereof |
| CN106822196A (en) * | 2017-03-23 | 2017-06-13 | 山东天智绿业生物科技有限公司 | A kind of method for extracting Ginkgo biloba polysaccharide and ginko leaves flavone simultaneously from ginkgo leaf |
-
1986
- 1986-04-30 JP JP61098181A patent/JPS62255431A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004002335A (en) * | 2002-03-28 | 2004-01-08 | Ortho Corporation | Agent for ameliorating symptom of indefinite complaint, food and composition thereof |
| CN106822196A (en) * | 2017-03-23 | 2017-06-13 | 山东天智绿业生物科技有限公司 | A kind of method for extracting Ginkgo biloba polysaccharide and ginko leaves flavone simultaneously from ginkgo leaf |
| CN106822196B (en) * | 2017-03-23 | 2020-07-07 | 山东天智绿业生物科技有限公司 | Method for simultaneously extracting ginkgo leaf polysaccharide and ginkgo leaf flavone from ginkgo leaves |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3048642B2 (en) | Method for obtaining nonpolar and polar extracts of turmeric and its use | |
| JP2010540572A (en) | A composition for treating hepatitis, comprising extracts of muyuyo flowers, leaves of thorny banci and turmeric roots | |
| JP2009269911A (en) | Anti-dementia active substance derived from hericium erinaceum and method for producing the same | |
| KR100382564B1 (en) | Herbal composition for prevention and treatment of alzheimer's disease | |
| JPH07274894A (en) | Food/beverage for preventing gastric ulcer | |
| US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
| KR100516180B1 (en) | Composition for anti-hyperlipidemia | |
| JP3294618B2 (en) | Harpagoside-rich extract from harpagofitsum procambens and method for producing the same | |
| KR100265385B1 (en) | Extract of rhodiola sp. for prevending and treating circulating diseases | |
| JPH07223940A (en) | Active oxygen eliminating agent and composition containing the same | |
| JPS62255431A (en) | Composition for normalizing liver function | |
| JPH07238027A (en) | Arterioscelerosis inhibitor and food or medicine containing the same | |
| WO2009031826A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
| JPH0753393A (en) | Arteriosclerosis-inhibiting agent and food or medicine containing the same | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JPS62255433A (en) | Composition for normalizing concentration of neutral fat in blood | |
| JPH03227985A (en) | Simple production of extract with high content of flavonoid from ginkgo leaf | |
| JPH08208501A (en) | Anti-hericobacter pylori medicine containing extract of garcinia mangostana l. | |
| WO2001039785A1 (en) | Formulation containing peanut leaf extract and its preparation | |
| JP3512118B2 (en) | Blood lipid improver | |
| CN112402411B (en) | Application of chalcone compound in preparation of sleep improvement medicine | |
| JPH06293654A (en) | Active oxygen scavenging agent and aldose reductase inhibiting agent | |
| JPH07238026A (en) | Arteriosclerosis inhibitor and food or medicine containing the same | |
| JPH0733672A (en) | Arteriosclerosis inhibitor and composition containing the same | |
| AU2008253777B2 (en) | Medicinal agent for treating patients suffering from diseases caused by the monoaminooxidase excessive activity and a method for treating patients suffering from diseases caused by the monoaminooxidase excessive activity |